Man Group plc Has $3.33 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Man Group plc grew its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 22.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,075 shares of the specialty pharmaceutical company's stock after purchasing an additional 4,890 shares during the period. Man Group plc's holdings in Jazz Pharmaceuticals were worth $3,334,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at approximately $25,000. Quadrant Capital Group LLC raised its holdings in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 101 shares in the last quarter. CoreFirst Bank & Trust acquired a new stake in Jazz Pharmaceuticals during the fourth quarter valued at $28,000. Allianz SE purchased a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $29,000. Finally, Jones Financial Companies Lllp increased its holdings in Jazz Pharmaceuticals by 75.1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock worth $37,000 after buying an additional 130 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 6,500 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $144.25, for a total value of $937,625.00. Following the completion of the sale, the chief executive officer now owns 464,058 shares in the company, valued at approximately $66,940,366.50. This trade represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the business's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. This represents a 10.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,236 shares of company stock valued at $3,956,190 in the last ninety days. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded up $1.09 during trading hours on Tuesday, hitting $109.16. 209,025 shares of the company's stock were exchanged, compared to its average volume of 849,602. The company's 50-day moving average price is $112.19 and its 200-day moving average price is $121.87. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06. The stock has a market capitalization of $6.73 billion, a price-to-earnings ratio of 15.30, a PEG ratio of 1.04 and a beta of 0.38. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. During the same quarter last year, the firm earned $2.68 earnings per share. The firm's quarterly revenue was down .5% compared to the same quarter last year. On average, sell-side analysts expect that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on JAZZ shares. Robert W. Baird reduced their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Piper Sandler reiterated an "overweight" rating and issued a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Morgan Stanley lowered their target price on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $182.79.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.